{"organizations": [], "uuid": "dc4cd8b75007399fa1caf2ccadbde96b2ce34431", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180124.html", "section_title": "Archive News &amp; Video for Wednesday, 24 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-novartis-new-ceo-sandoz-remains-pi/brief-novartis-new-ceo-sandoz-remains-pillar-despite-u-s-business-review-idUSZ8N15A01L", "country": "US", "domain_rank": 408, "title": "BRIEF-Novartis new CEO: Sandoz remains pillar, despite U.S. business review", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-24T19:03:00.000+02:00", "replies_count": 0, "uuid": "dc4cd8b75007399fa1caf2ccadbde96b2ce34431"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-novartis-new-ceo-sandoz-remains-pi/brief-novartis-new-ceo-sandoz-remains-pillar-despite-u-s-business-review-idUSZ8N15A01L", "ord_in_thread": 0, "title": "BRIEF-Novartis new CEO: Sandoz remains pillar, despite U.S. business review", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "novartis", "sentiment": "negative"}, {"name": "sandoz", "sentiment": "negative"}, {"name": "alcon", "sentiment": "none"}, {"name": "gsk", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 24 (Reuters) - Novartis:\n* INCOMING CEO SAYS OPTIMISTIC ABOUT SOLID SALES GROWTH OVER NEXT FIVE YEARS\n* INCOMING CEO SAYS PRICE PRESSURE ON SANDOZ IN UNITED STATES CAUSING COMPANY TO LOOK AGGRESSIVELY AT RESHAPING U.S. GENERIC PORTFOLIO\n* INCOMING CEO SAYS HAS NOT YET MADE ANY DECISIONS ON SANDOZ‘S ORAL SOLIDS GENERICS BUSINESS IN U.S., UNDER REVIEW\n* INCOMING CEO SAYS INITIALLY SAW “BUMPS” IN KYMRIAH ROLLOUT IN PEDIATRIC ALL, NOW SEES ACCELERATION\n* INCOMING CEO SAYS NO CHANGE TO NOVARTIS‘S POSITION ON GSK JOINT VENTURE OR ROCHE STAKE\n* INCOMING CEO SAYS ALMOST EVERY PATIENT IN KYMRIAH LAUNCH HAS UNIQUE INSURANCE REIMBURSEMENT PROFILE, STILL CONSIDERING PRICING MODEL FOR ADDITIONAL INDICATIONS\n* INCOMING CEO SAYS NO ACTION ON ALCON SPINOFF BEFORE FIRST HALF 2019\n* INCOMING CEO SAYS ON TRACK TO DELIVER CORE MARGIN EXPANSION IN 2018\n* INCOMING CEO SAYS WE CONTINUE TO HOLD TO OUR STRATEGY OF BOLT-ON ACQUISITIONS TO SUPPORT CORE AREAS INCLUDING ONCOLOGY\n* GENERAL COUNSEL SAYS “LOOKING AT ALL OPPORTUNITIES” WITH REGARDS TO RESOLVING U.S. DOJ LEGAL ACTION TARGETING SPEAKERS PROGRAM\n* INCOMING CEO SAYS SANDOZ REMAINS PILLAR, DESPITE REVIEW OF U.S. GENERICS BUSINESS AMID PRICE PRESSURE Source text for Eikon: Further company coverage: (Reporting by John Miller)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-24T19:03:00.000+02:00", "crawled": "2018-01-25T12:59:21.023+02:00", "highlightTitle": ""}